Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio C Chavez

Showing results (71-80 of 132) with videos related to

Pageof 14
Sort By:
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
Neuro-Oncology|September 1, 2016
Long-term survival in AIDS-related primary central nervous system lymphomaNeel K Gupta, Amber Nolan, Antonio Omuro, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 studyJulio C Chavez, Michael Dickinson, Javier Munoz, et al.
Pageof 14

Showing results (71-80 of 132) with videos related to

Sort By:
Pageof 14
Nature Medicine|March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialSattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
American Journal of Hematology|June 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell LymphomaJulio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, et al.
Blood Advances|February 12, 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent modelWael Gamal, Nienke B Goedhart, Helga Simon-Molas, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
Neuro-Oncology|September 1, 2016
Long-term survival in AIDS-related primary central nervous system lymphomaNeel K Gupta, Amber Nolan, Antonio Omuro, et al.
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 studyJulio C Chavez, Michael Dickinson, Javier Munoz, et al.
Pageof 14